Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Published on by Neuroscientists

Assoc. Prof. Dr. Izabela Małysz-Cymborska | Neurogenetics | Best Researcher Award

Assoc. Prof. Dr. Izabela Małysz-Cymborska,  Department of Neurology and Neurosurgery, School of Medicine, University of Warmia and Mazury, Poland.

Dr. Izabela Małysz-Cymborska is a distinguished biomedical researcher and Associate Professor in Neurosurgery at the University of Warmia and Mazury, Poland. Her academic path began with a Master’s in Biology and culminated in a Ph.D. focused on hormonal mechanisms, followed by a Habilitation in Medicine. Her research spans neuroregeneration, stem cell therapy, and immunomodulatory strategies for neurological diseases such as ALS and stroke. She has led and contributed to nationally funded projects like NanoTech4ALS, Explore Me, and her current OPUS-funded investigation using a swine model for stroke therapy. Her interdisciplinary approach bridges molecular biology, reproductive science, and clinical neuroscience, demonstrating a rare ability to translate foundational research into therapeutic innovation.

Profile

Google Scholar

🎓 Early Academic Pursuits

Dr. Izabela Małysz-Cymborska embarked on her academic journey with a deep-rooted interest in biological sciences. Born on September 21, 1985, in Poland, she pursued her undergraduate studies at the University of Warmia and Mazury in Olsztyn, earning a Master of Science degree in Biology in 2009. Her passion for advanced biomedical research led her to the Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, where she completed her Ph.D. in 2015. Her doctoral research, grounded in hormonal action mechanisms, laid the foundation for her future contributions to neurobiology and regenerative medicine.

🧠 Professional Endeavors in Neuroscience

Dr. Małysz-Cymborska’s postdoctoral and professional journey has been largely rooted in neuroscientific investigation, with a special focus on neuroregeneration and stroke therapy. Since 2021, she has held the position of Associate Professor in the Department of Neurosurgery at the University of Warmia and Mazury. Her early postdoctoral fellowships (2015–2018) focused on pioneering work in the application of glial progenitors and stem cells in neurological disorders like ALS. These formative experiences not only enriched her research trajectory but also provided a vital bridge between animal studies and translational medicine.

🧪 Research Focus and Scientific Contributions

Dr. Małysz-Cymborska’s research portfolio reflects a consistent dedication to understanding complex neural pathologies and their treatment through regenerative approaches. She has led and contributed to several national and international projects, including NanoTech4ALS, which investigated MRI-monitored transplantation techniques using hydrogel carriers for ALS treatment. Her current role as Principal Investigator in the OPUS-funded project explores an endovascular model of stroke in swine, opening new therapeutic pathways for immunomodulation. She has also delved into reproductive biology, investigating the influence of gonadotropins on prostaglandin synthesis and the function of the corpus luteum, showcasing her multidisciplinary expertise.

🧬 Bridging Regeneration and Technology

A major hallmark of Dr. Małysz-Cymborska’s work is the integration of regenerative medicine and cutting-edge biomedical technologies. Her involvement in Explore Me and NanoTech4ALS demonstrated her commitment to merging cellular therapy with advanced biomaterials and imaging. These projects explored the therapeutic potential of mesenchymal stem cells and human glial progenitors for neurodegenerative conditions, reflecting her drive to push boundaries in translational medicine and neurosurgery.

🏅 Accolades and Recognition

Dr. Małysz-Cymborska’s scientific accomplishments were recognized through her Habilitation Degree in Medicine, awarded in 2022 by the University of Warmia and Mazury—a prestigious academic achievement in Poland that underscores her contributions to the medical sciences. Additionally, her appointment as the Dean’s representative for animal experiments between 2018 and 2019 further illustrates the trust and respect she commands within her institution and the research community.

🌍 Impact and Influence in Translational Neuroscience

Her work has had significant implications not only in Poland but also across the global neuroscience landscape. By focusing on models that simulate real-world human neurological disorders, such as swine models for stroke and ALS, she has established platforms that can more accurately predict treatment outcomes in humans. Her collaborative efforts within national strategic medical programs have enriched the broader field of translational neuroscience, particularly in immune response modulation and neural repair mechanisms.

🔮 Legacy and Future Contributions

As her OPUS project continues until 2025, Dr. Izabela Małysz-Cymborska is poised to deliver crucial insights into stroke immunotherapy. Her legacy lies in her ability to traverse boundaries between endocrinology, neurobiology, and regenerative therapy—crafting a unique niche that advances both fundamental science and clinical application. With a promising trajectory ahead, she is set to influence future protocols in neurovascular therapy, offering hope to patients with currently untreatable conditions.

Publication

  • Hydrogel-based scaffolds to support intrathecal stem cell transplantation as a gateway to the spinal cord: clinical needs, biomaterials, and imaging technologies
    Authors: JM Oliveira, L Carvalho, J Silva-Correia, S Vieira, M Majchrzak, …
    Year: 2018

 

  • Advances in bioinks and in vivo imaging of biomaterials for CNS applications
    Authors: EP Oliveira, I Malysz-Cymborska, D Golubczyk, L Kalkowski, …
    Year: 2019

 

  • The role of glia in canine degenerative myelopathy: relevance to human amyotrophic lateral sclerosis
    Authors: D Golubczyk, I Malysz-Cymborska, L Kalkowski, M Janowski, JR Coates, …
    Year: 2019

 

  • Methacrylated gellan gum and hyaluronic acid hydrogel blends for image-guided neurointerventions
    Authors: S Vieira, P Strymecka, L Stanaszek, J Silva-Correia, K Drela, …
    Year: 2020

 

  • MRI-guided intrathecal transplantation of hydrogel-embedded glial progenitors in large animals
    Authors: I Malysz-Cymborska, D Golubczyk, L Kalkowski, A Burczyk, M Janowski, …
    Year: 2018

 

  • Endovascular model of ischemic stroke in swine guided by real-time MRI
    Authors: D Golubczyk, L Kalkowski, J Kwiatkowska, M Zawadzki, P Holak, J Glodek, …
    Year: 2020

 

  • Expression of the vascular endothelial growth factor receptor system in porcine oviducts after induction of ovulation and superovulation
    Authors: I Małysz-Cymborska, A Andronowska
    Year: 2014

 

  • Rabbit model of human gliomas: implications for intra-arterial drug delivery
    Authors: H Qin, M Janowski, MS Pearl, I Malysz-Cymborska, S Li, CG Eberhart, …
    Year: 2017

 

  • Two in one: use of divalent manganese ions as both cross-linking and MRI contrast agent for intrathecal injection of hydrogel-embedded stem cells
    Authors: L Kalkowski, D Golubczyk, J Kwiatkowska, P Holak, K Milewska, …
    Year: 2021

 

  • Effect of hCG and eCG treatments on Prostaglandins Synthesis in the Porcine Oviduct
    Authors: I Małysz‐Cymborska, AJ Ziecik, A Waclawik, A Andronowska
    Year: 2013

 

🧾 Conclusion

Dr. Małysz-Cymborska’s career reflects a compelling fusion of scientific curiosity, clinical relevance, and academic rigor. With notable achievements in regenerative medicine and translational neuroscience, she continues to shape the future of therapeutic interventions for complex neurological disorders. Her ongoing research promises to pave the way for advanced stroke treatments and immune-based neurotherapies, cementing her role as a key contributor to modern biomedical science.

Pongrama Ramasoota | Molecular and Cellular Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Dr. Pongrama Ramasoota | Molecular and Cellular Neuroscience | Best Researcher Award

Prof. Dr. Pongrama Ramasoota, Mahidol University, Thailand.

Dr. Pongrama Ramasoota is a distinguished professor and researcher specializing in antibody research and virology at the Centre of Excellence for Antibody Research (CEAR), Mahidol University, Thailand. With a strong academic foundation in veterinary medicine, public health, and microbiology, he has dedicated his career to developing therapeutic and diagnostic monoclonal antibodies against viruses such as Dengue, Rabies, Foot and Mouth Disease, and Influenza. His contributions extend beyond infectious disease research, as he has also explored anti-aging supplements for humans and pets. Recognized with numerous national and international awards, his research has significantly impacted medical biotechnology, earning him a reputation as a leading scientist in his field.

 

Profile

Scopus

 

🎓 Early Academic Pursuits

Pongrama Ramasoota’s journey into the world of microbiology and antibody research began with a solid foundation in veterinary medicine. He earned his Doctor of Veterinary Medicine from Kasetsart University, where his fascination with infectious diseases and immunology took root. His academic pursuits led him to Mahidol University, where he obtained a Master of Public Health, further broadening his expertise in disease prevention and control. Driven by a passion for scientific exploration, he pursued a Master of Science and Ph.D. in Microbiology at the prestigious Swedish University of Agricultural Sciences in Uppsala, Sweden. These formative years were instrumental in shaping his career as a leading researcher in antibody development and disease management.

🏥 Professional Endeavors

As a distinguished professor at the Centre of Excellence for Antibody Research (CEAR) within the Faculty of Tropical Medicine, Mahidol University, Dr. Ramasoota has dedicated his career to advancing the field of immunotherapy. His research primarily focuses on developing neutralizing monoclonal antibodies to combat viral threats such as Dengue and Rabies. Over the years, he has led groundbreaking projects aimed at creating effective therapeutic and diagnostic solutions. His expertise has also extended beyond academia, as he collaborates with industry leaders to translate research into practical applications that benefit global health.

🦠 Contributions and Research Focus

Dr. Ramasoota’s contributions to medical research are vast and impactful. His work on neutralizing human monoclonal antibodies against Dengue and Rabies viruses has paved the way for potential life-saving treatments. His research extends to diagnostic monoclonal antibodies for detecting Foot and Mouth Disease Virus (FMDV) and Influenza, significantly enhancing disease surveillance. Beyond infectious diseases, he has also ventured into anti-aging research, developing natural supplements to promote longevity in both humans and pets. His relentless pursuit of innovation continues to drive advancements in virology, immunotherapy, and biotechnology.

🏆 Accolades and Recognition

Dr. Ramasoota’s contributions to science have been recognized with numerous prestigious awards. He was honored as Thailand’s Outstanding Researcher in 2020 and named Thailand’s Outstanding Veterinarian in 2016. His innovative work earned him multiple Outstanding Research and Invention Awards from the National Research Council of Thailand between 2008 and 2016. He has also received international recognition, including a gold medal from the 2014 Taipei Invention & Techno Mart and awards from the Korea Invention Association and the International Federation of Inventors’ Associations. These accolades underscore his influence as a pioneer in antibody research and biotechnology.

🌍 Impact and Influence

With an H-index of 18 and over 1,038 citations on Scopus, Dr. Ramasoota’s research has significantly influenced the scientific community. His findings have been instrumental in shaping new treatment strategies for viral diseases, providing hope for better therapeutic interventions. Collaborating with industry leaders such as Advy Chemical (India) and Thai-Naoka (Thailand), he has helped bridge the gap between research and real-world applications. His contributions to diagnostic tools and monoclonal antibody therapies continue to shape the future of virology and medical biotechnology.

📚 Legacy and Future Contributions

Beyond his research endeavors, Dr. Ramasoota has authored books that highlight his expertise in environmental management and anti-aging technologies. His book Hallmarks of Aging, Technology and Innovation for Anti-Aging explores groundbreaking advancements in longevity research, demonstrating his commitment to improving human health across various dimensions. As he continues to innovate, his legacy as a leading researcher in antibody development and viral immunotherapy will inspire future generations of scientists. His ongoing efforts to combat infectious diseases and promote healthier aging promise a lasting impact on global health and biotechnology.

Publication

  1. Title: Development of novel canine phage display-derived neutralizing monoclonal antibody fragments against rabies virus from immunized dogs
    Authors: A. Chorpunkul, U. Boonyuen, K. Limkittikul, P. Lekcharoensuk, P. Ramasoota
    Year: 2024

 

  1. Title: Characterization of Vibrio parahaemolyticus isolated from clinical specimens and oysters in Thailand
    Authors: N. Tewawong, S. Kowaboot, S. Kengkarn, P. Ramasoota, O. Suthienkul
    Year: 2024

 

  1. Title: Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody
    Authors: S. Krittanai, K. Rattanapisit, C.J.I. Bulaon, R. Strasser, W. Phoolcharoen
    Year: 2024

 

  1. Title: Associations of effort-reward imbalance at work and quality of life among workers after stroke: a one-year longitudinal study in Thailand
    Authors: S. Naknoi, J. Li, P. Ramasoota, N. Soonthornworasiri, O. Kaewboonchoo
    Year: 2023

 

  1. Title: Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and Zika Virus Infections
    Authors: R. Sootichote, W. Puangmanee, S. Benjathummarak, P. Ramasoota, P. Pitaksajjakul
    Year: 2023

 

  1. Title: A replication competent luciferase-secreting DENV2 reporter for sero-epidemiological surveillance of neutralizing and enhancing antibodies
    Authors: K. Saipin, B.K. Thaisomboonsuk, B. Siridechadilok, N. Sittisombut, J. Junjhon
    Year: 2022

 

  1. Title: Spread of a Novel Indian Ocean Lineage Carrying E1‐K211E/E2‐V264A of Chikungunya Virus East/Central/South African Genotype across the Indian Subcontinent, Southeast Asia, and Eastern Africa
    Authors: J. Phadungsombat, H.A. Imad, E.E. Nakayama, W. Piyaphanee, T. Shioda
    Year: 2022

 

🎯 Conclusion

Dr. Ramasoota’s work has not only advanced scientific knowledge but also contributed to real-world solutions in disease treatment and diagnostics. His collaborations with industries and commitment to innovation ensure that his research continues to benefit global health. As he continues to push the boundaries of antibody research and anti-aging science, his legacy will inspire future generations of scientists, leaving a lasting impact on virology, immunotherapy, and biotechnology.

 

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Published on by Neuroscientists

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.